Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. ESPR has been the topic of several other reports. Needham & Company LLC dropped their price target on shares of Esperion […]
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. ESPR has been the topic of several other reports. Needham & Company LLC dropped their price target on shares of Esperion […]
